Aronex Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 15-11-2024
- Paid Up Capital ₹ 1.28 M
as on 15-11-2024
- Company Age 21 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.00 M
as on 15-11-2024
- Revenue -18.15%
(FY 2023)
- Profit -44.97%
(FY 2023)
- Ebitda -45.61%
(FY 2023)
- Net Worth 14.44%
(FY 2023)
- Total Assets 0.67%
(FY 2023)
About Aronex Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.28 M.
The company has closed loans amounting to ₹2.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sanjay Tulsyan and Chaitanya Tulsyan serve as directors at the Company.
- CIN/LLPIN
U24231GJ2003PTC043081
- Company No.
043081
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Aronex Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Tulsyan  | Managing Director | 20-Oct-2003 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chaitanya Tulsyan | Whole-Time Director | 01-Jun-2021 | Current |
Financial Performance of Aronex Life Sciences.
Aronex Life Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 18.15% decrease. The company also saw a substantial fall in profitability, with a 44.97% decrease in profit. The company's net worth Soared by an impressive increase of 14.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aronex Life Sciences?
In 2022, Aronex Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zenon Lifesciences Private LimitedActive 9 years 8 monthsSanjay Tulsyan and Chaitanya Tulsyan are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 09 Apr 2008 | ₹2.00 M | Satisfied |
How Many Employees Work at Aronex Life Sciences?
Unlock and access historical data on people associated with Aronex Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aronex Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aronex Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
